LIFECORE BIOMEDICAL, INC. \DE\
Datakwaliteit: 83%
LFCR
Nasdaq
Manufacturing
Chemicals
€ 4,75
▲
€ 0,03
(0,64%)
Marktkapitalisatie: 176,89 M
Prijs
€ 4,72
Marktkapitalisatie
176,89 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—
Quick Summary
Belangrijkste Punten
Earnings declined -249,51% over the past year
Generating 7,69 M in free cash flow
ROIC of 2,99% — low return on invested capital
Interest coverage of 0,35× — tight debt servicing
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)-249,51%
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
N/A
ROIC2,99%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio2,80
Interest Coverage0,35
Waardering
PE (TTM)
-15,09
Onder sectorgemiddelde (-1,47)
P/B RatioN/A
EV/EBITDA18,61
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -15,1 | -1,5 |
| P/B | — | 1,6 |
| ROE % | — | -53,3 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
Koersdoel Analisten
3 analisten
Buy
Huidig
€ 4,75
Koersdoel
€ 6,50
€ 5,00
€ 5,50
€ 9,00
Vooruitzicht
Forward K/W
-5,72
Forward WPA
-€ 0,87
Omzet Sch.
131,15 M
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2027 |
-€ 0,87
-€ 0,96 – -€ 0,78
|
131,15 M | 4 |
| FY2026 |
-€ 0,89
-€ 0,93 – -€ 0,86
|
122,68 M | 4 |
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| 2026 Q2 |
-€ 0,21
-€ 0,24 – -€ 0,16
|
29,89 M | 4 |
| 2026 Q1 |
-€ 0,29
-€ 0,33 – -€ 0,24
|
25,96 M | 4 |
Winstverassingen
Laatste 5 kwartalen
| Kwartaal | Geschat WPA | Werkelijk WPA | Verrassing |
|---|---|---|---|
| Q42025 | -€ 0,16 | -€ 0,16 | 0,0% |
| 2026-Q1 | -€ 0,29 | -€ 0,29 | 0,0% |
| Q12025 | -€ 0,15 | -€ 0,47 | -213,3% |
| Q42024 | -€ 0,29 | -€ 0,25 | +13,8% |
| Q32024 | -€ 0,49 | -€ 0,53 | -8,9% |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | -249,51% | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -11,72 M |
| ROE | N/A | ROA | -4,96% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | 7,69 M |
| ROIC | 2,99% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 2,80 |
| Interest Coverage | 0,35 | Asset Turnover | N/A |
| Working Capital | 53,97 M | Tangible Book Value | -28,62 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -15,09 | Forward P/E | N/A |
| P/B Ratio | N/A | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | 18,61 | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 4,35% | ||
| Market Cap | 176,89 M | Enterprise Value | 293,99 M |
| Per Share | |||
| EPS (Diluted TTM) | -0,30 | Revenue / Share | N/A |
| FCF / Share | 0,21 | OCF / Share | 0,26 |
| EPS CAGR (1Y) | -268,75% | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -65,64% |
| SBC-Adj. FCF | -3,04 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -17,96 M | 12,01 M | -97,43 M | -99,56 M | -32,67 M |
| EPS (Diluted) | -0,54 | 0,32 | -3,31 | -3,32 | -1,12 |
| Gross Profit | 23,69 M | 41,85 M | 50,37 M | 27,99 M | 81,47 M |
| Operating Income | -733.000,0 | -8,84 M | -41,29 M | -21,80 M | -13,50 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 4,97 M | 8,58 M | 7,84 M | 8,74 M | 10,22 M |
| SG&A Expenses | 19,46 M | 40,46 M | 46,13 M | 38,97 M | 65,36 M |
| D&A | 8,03 M | 8,86 M | 17,88 M | 13,29 M | 19,87 M |
| Interest Expense | 15,85 M | — | 17,36 M | 17,65 M | — |
| Income Tax | 337.000,0 | 183.000,0 | -5,84 M | 308.000,0 | -7,80 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2022 | FY2023 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 232,18 M | 253,96 M | 295,16 M | 253,55 M | 502,92 M |
| Total Liabilities | 198,12 M | 200,06 M | 187,22 M | 218,46 M | 300,14 M |
| Shareholders' Equity | -14,20 M | 11,32 M | 107,95 M | -4,23 M | 202,78 M |
| Total Debt | 142,24 M | 101,59 M | 98,18 M | 84,84 M | 164,90 M |
| Cash & Equivalents | 17,47 M | 8,46 M | 1,64 M | 19,09 M | 1,30 M |
| Current Assets | 82,29 M | 81,03 M | 123,71 M | 93,88 M | 148,32 M |
| Current Liabilities | 23,57 M | 38,87 M | 79,23 M | 39,29 M | 101,89 M |
{"event":"ticker_viewed","properties":{"ticker":"LFCR","listing_kind":"stock","pathname":"/stocks/lfcr","exchange":"Nasdaq","country":"US"}}